Director Jeanne Thoma receives 4,357-share grant at ANI Pharmaceuticals (ANIP)

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Thoma Jeanne reported acquisition or exercise transactions in this Form 4 filing.

ANI Pharmaceuticals director Jeanne Thoma received a new equity grant. She was awarded 4,357 shares of ANI Pharmaceuticals common stock as a restricted stock award, with no cash paid per share. After this grant, she directly holds 27,762 common shares.

The restricted stock award will vest in full on May 21, 2027, meaning she will gain full ownership of these shares on that date if the vesting conditions are satisfied.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Thoma Jeanne

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	4,357	$0.00	--

Holdings After Transaction: Common Stock — 27,762 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Restricted stock granted: 4,357 shares Grant price per share: $0.00 per share Total shares after grant: 27,762 shares +1 more

4 metrics

Restricted stock granted 4,357 shares Restricted stock award to director Jeanne Thoma

Grant price per share $0.00 per share Equity compensation grant, no cash paid

Total shares after grant 27,762 shares Direct holdings following the award

Vesting date May 21, 2027 Restricted stock award vests in full

Key Terms

restricted stock award, Form 4, non-derivative, vesting

4 terms

restricted stock award financial

"Represents a restricted stock award that will vest in full on May 21, 2027."

A restricted stock award is company shares given to an employee or executive that cannot be sold or fully owned until certain conditions—like staying with the company for a set time or hitting performance targets—are met. Think of it as a gift that only becomes yours after you fulfill specific obligations; for investors, these awards matter because they can increase the total shares outstanding when they vest, reveal how management is being paid and motivated, and create potential selling pressure when restrictions lift.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

non-derivative financial

""transaction_type": "non-derivative""

vesting financial

"restricted stock award that will vest in full on May 21, 2027."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/10/2026 - 09:10 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thoma Jeanne

(Last)

(First)

(Middle)

C/O ANI PHARMACEUTICALS, INC.

104 CARNEGIE CENTER, SUITE 300

(Street)

PRINCETON

NEW JERSEY

08540

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/21/2026		A⁽¹⁾		4,357	A	$0	27,762	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents a restricted stock award that will vest in full on May 21, 2027.

Remarks:

	/s/ Jeanne A. Thoma, by attorney-in-fact Meredith W. Cook	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did ANI Pharmaceuticals (ANIP) report for Jeanne Thoma?

ANI Pharmaceuticals reported that director Jeanne Thoma received a grant of 4,357 shares of common stock as a restricted stock award. This is a compensation-related equity grant, not an open-market purchase or sale of shares.

How many ANI Pharmaceuticals (ANIP) shares does Jeanne Thoma hold after this grant?

Following the restricted stock award, Jeanne Thoma directly holds 27,762 shares of ANI Pharmaceuticals common stock. This total includes the newly granted 4,357 restricted shares, which are subject to vesting conditions until May 21, 2027.

When does Jeanne Thoma’s restricted stock award in ANI Pharmaceuticals (ANIP) vest?

The restricted stock award to Jeanne Thoma will vest in full on May 21, 2027. At that time, assuming conditions are met, the 4,357 restricted shares become fully owned and no longer subject to forfeiture restrictions.

Did Jeanne Thoma buy or sell ANI Pharmaceuticals (ANIP) shares in the market?

No market buy or sell occurred in this filing. Jeanne Thoma received 4,357 ANI Pharmaceuticals shares as a restricted stock award, a compensation grant with a zero dollar per-share price rather than an open-market transaction.

What does the Form 4 for ANI Pharmaceuticals (ANIP) indicate about derivative securities?

The Form 4 shows no derivative security transactions for this event. The filing lists only a non-derivative restricted stock award of 4,357 common shares and reports total direct holdings of 27,762 ANI Pharmaceuticals shares following the grant.